James Michael Kirshenbaum, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pericardiocentesis | 1 | 2017 | 78 | 0.550 |
Why?
|
| Cardiac Tamponade | 2 | 2017 | 175 | 0.530 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2014 | 167 | 0.410 |
Why?
|
| Tissue Plasminogen Activator | 5 | 2010 | 1166 | 0.370 |
Why?
|
| Thrombosis | 3 | 2014 | 2956 | 0.340 |
Why?
|
| Tricuspid Valve | 3 | 2019 | 419 | 0.330 |
Why?
|
| Myocarditis | 2 | 2014 | 804 | 0.310 |
Why?
|
| Thrombolytic Therapy | 6 | 2010 | 2058 | 0.290 |
Why?
|
| Foramen Ovale, Patent | 2 | 2019 | 210 | 0.270 |
Why?
|
| Dyspnea | 3 | 2019 | 1352 | 0.260 |
Why?
|
| Propanolamines | 5 | 1989 | 164 | 0.250 |
Why?
|
| Tricuspid Valve Insufficiency | 2 | 2019 | 362 | 0.240 |
Why?
|
| Heart | 4 | 2014 | 4451 | 0.230 |
Why?
|
| Diazepam | 2 | 2020 | 215 | 0.210 |
Why?
|
| Fibrinolytic Agents | 2 | 2010 | 2082 | 0.180 |
Why?
|
| Defibrillators, Implantable | 1 | 2010 | 1498 | 0.170 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2019 | 1557 | 0.170 |
Why?
|
| Adenocarcinoma | 1 | 2017 | 6400 | 0.160 |
Why?
|
| Hydroxychloroquine | 2 | 2020 | 427 | 0.160 |
Why?
|
| Adrenergic beta-Antagonists | 6 | 1992 | 1244 | 0.150 |
Why?
|
| Angioplasty, Balloon, Coronary | 6 | 2010 | 1724 | 0.150 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2018 | 134 | 0.140 |
Why?
|
| Heart Diseases | 1 | 2010 | 2816 | 0.140 |
Why?
|
| Myocardial Infarction | 13 | 2010 | 11515 | 0.130 |
Why?
|
| Medication Reconciliation | 1 | 2018 | 153 | 0.130 |
Why?
|
| Pharmacists | 1 | 2018 | 261 | 0.130 |
Why?
|
| Brain Neoplasms | 1 | 2017 | 9182 | 0.120 |
Why?
|
| Professional Role | 1 | 2018 | 316 | 0.120 |
Why?
|
| Diagnosis, Differential | 7 | 2019 | 13026 | 0.120 |
Why?
|
| Heart Valve Prosthesis | 2 | 2015 | 1468 | 0.120 |
Why?
|
| Plasmapheresis | 1 | 2014 | 207 | 0.110 |
Why?
|
| Urokinase-Type Plasminogen Activator | 2 | 1991 | 325 | 0.110 |
Why?
|
| Coronary Disease | 10 | 2000 | 5926 | 0.110 |
Why?
|
| Cough | 1 | 2017 | 598 | 0.100 |
Why?
|
| Infusions, Intravenous | 5 | 2010 | 2228 | 0.100 |
Why?
|
| Echocardiography | 5 | 2019 | 5043 | 0.100 |
Why?
|
| Lung Neoplasms | 1 | 2017 | 13589 | 0.100 |
Why?
|
| Fatal Outcome | 1 | 2017 | 1840 | 0.100 |
Why?
|
| Endocarditis | 1 | 2015 | 355 | 0.090 |
Why?
|
| Shock, Cardiogenic | 1 | 2017 | 711 | 0.090 |
Why?
|
| Suicide, Attempted | 1 | 2020 | 1409 | 0.090 |
Why?
|
| Prosthesis-Related Infections | 1 | 2015 | 491 | 0.090 |
Why?
|
| Coronary Circulation | 2 | 2014 | 1617 | 0.080 |
Why?
|
| Myocardium | 2 | 2014 | 4788 | 0.080 |
Why?
|
| Lymphatic Metastasis | 1 | 2017 | 2930 | 0.080 |
Why?
|
| Vena Cava, Superior | 1 | 2010 | 197 | 0.080 |
Why?
|
| Exercise Test | 3 | 2014 | 2186 | 0.080 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2010 | 168 | 0.080 |
Why?
|
| Anticoagulants | 3 | 2014 | 4840 | 0.080 |
Why?
|
| Electrocardiography | 6 | 2014 | 6410 | 0.070 |
Why?
|
| Meningitis, Meningococcal | 1 | 1987 | 43 | 0.070 |
Why?
|
| Heart Neoplasms | 1 | 2010 | 374 | 0.070 |
Why?
|
| Catheters, Indwelling | 2 | 2019 | 436 | 0.070 |
Why?
|
| Thiophenes | 1 | 2010 | 570 | 0.070 |
Why?
|
| Ticlopidine | 1 | 2010 | 730 | 0.060 |
Why?
|
| Pericarditis | 1 | 1987 | 136 | 0.060 |
Why?
|
| Hemodynamics | 6 | 1989 | 4202 | 0.060 |
Why?
|
| Angioplasty, Balloon | 3 | 2001 | 592 | 0.060 |
Why?
|
| Lung Diseases, Fungal | 1 | 1985 | 125 | 0.060 |
Why?
|
| Catheterization | 1 | 2010 | 1431 | 0.060 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2010 | 2768 | 0.060 |
Why?
|
| Pulmonary Embolism | 3 | 2019 | 2591 | 0.060 |
Why?
|
| Heart-Assist Devices | 1 | 2014 | 1292 | 0.050 |
Why?
|
| Organotechnetium Compounds | 3 | 1991 | 133 | 0.050 |
Why?
|
| Heart Atria | 1 | 2010 | 1361 | 0.050 |
Why?
|
| Aspergillosis | 1 | 1985 | 242 | 0.050 |
Why?
|
| Cardiology | 1 | 2014 | 1701 | 0.050 |
Why?
|
| Platelet Aggregation | 2 | 2001 | 772 | 0.050 |
Why?
|
| Coronary Thrombosis | 3 | 1991 | 440 | 0.050 |
Why?
|
| Biopsy | 1 | 2014 | 6816 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3116 | 0.050 |
Why?
|
| Thromboembolism | 2 | 2019 | 1006 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3240 | 0.050 |
Why?
|
| Prognosis | 4 | 2017 | 30028 | 0.050 |
Why?
|
| Positron-Emission Tomography | 1 | 2017 | 6657 | 0.040 |
Why?
|
| Angina Pectoris, Variant | 1 | 2000 | 53 | 0.040 |
Why?
|
| Humans | 45 | 2020 | 768451 | 0.040 |
Why?
|
| Piperazines | 1 | 2010 | 2546 | 0.040 |
Why?
|
| Diagnostic Imaging | 1 | 2014 | 3543 | 0.040 |
Why?
|
| Treatment Outcome | 4 | 2020 | 65409 | 0.040 |
Why?
|
| Male | 32 | 2020 | 364781 | 0.040 |
Why?
|
| Middle Aged | 26 | 2017 | 223418 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2010 | 3458 | 0.040 |
Why?
|
| Heart Valve Prosthesis Implantation | 2 | 2019 | 1569 | 0.040 |
Why?
|
| Vasodilator Agents | 3 | 2003 | 991 | 0.040 |
Why?
|
| Nitriles | 3 | 1991 | 984 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2010 | 2190 | 0.040 |
Why?
|
| Angina, Unstable | 2 | 1999 | 893 | 0.040 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2000 | 538 | 0.040 |
Why?
|
| Tyrosine | 1 | 2001 | 1428 | 0.030 |
Why?
|
| Pulmonary Artery | 1 | 1985 | 1949 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2010 | 5995 | 0.030 |
Why?
|
| Potassium | 1 | 2020 | 1319 | 0.030 |
Why?
|
| Adult | 16 | 2020 | 223542 | 0.030 |
Why?
|
| Coronary Angiography | 7 | 2003 | 4526 | 0.030 |
Why?
|
| Anistreplase | 1 | 1994 | 11 | 0.030 |
Why?
|
| Female | 29 | 2019 | 396943 | 0.030 |
Why?
|
| Technetium | 2 | 1986 | 326 | 0.030 |
Why?
|
| Coronary Artery Disease | 2 | 2014 | 6551 | 0.030 |
Why?
|
| Carbon Dioxide | 1 | 2019 | 1152 | 0.030 |
Why?
|
| Heart Transplantation | 4 | 1989 | 3291 | 0.030 |
Why?
|
| Immunosuppressive Agents | 2 | 1989 | 4213 | 0.030 |
Why?
|
| Myocardial Reperfusion | 2 | 1991 | 339 | 0.030 |
Why?
|
| Sepsis | 1 | 1987 | 2602 | 0.030 |
Why?
|
| Cardiovascular Diseases | 1 | 2018 | 15638 | 0.030 |
Why?
|
| Vascular Patency | 2 | 1994 | 916 | 0.020 |
Why?
|
| Hypercholesterolemia | 2 | 1989 | 1142 | 0.020 |
Why?
|
| Cause of Death | 1 | 2003 | 3727 | 0.020 |
Why?
|
| Scoliosis | 1 | 2019 | 793 | 0.020 |
Why?
|
| Organometallic Compounds | 2 | 1986 | 649 | 0.020 |
Why?
|
| Recombinant Proteins | 2 | 1991 | 6527 | 0.020 |
Why?
|
| Pandemics | 2 | 2020 | 8753 | 0.020 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 1991 | 425 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 1991 | 1379 | 0.020 |
Why?
|
| Lovastatin | 1 | 1989 | 115 | 0.020 |
Why?
|
| Enzyme Precursors | 1 | 1989 | 168 | 0.020 |
Why?
|
| Plasminogen Activators | 1 | 1989 | 199 | 0.020 |
Why?
|
| Carcinoma in Situ | 1 | 1974 | 791 | 0.020 |
Why?
|
| Stents | 1 | 2000 | 3204 | 0.020 |
Why?
|
| Streptokinase | 1 | 1988 | 186 | 0.020 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2010 | 284 | 0.020 |
Why?
|
| Fibrinogen | 1 | 1991 | 892 | 0.020 |
Why?
|
| Nitrates | 1 | 1989 | 260 | 0.020 |
Why?
|
| Fat Necrosis | 1 | 1988 | 60 | 0.020 |
Why?
|
| Radiography | 1 | 2019 | 6995 | 0.020 |
Why?
|
| Tachycardia | 1 | 2010 | 599 | 0.020 |
Why?
|
| Aged | 15 | 2018 | 171520 | 0.020 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 1988 | 278 | 0.020 |
Why?
|
| Nitroglycerin | 2 | 1988 | 332 | 0.020 |
Why?
|
| Patient Selection | 1 | 1999 | 4266 | 0.020 |
Why?
|
| Hypertension, Pulmonary | 2 | 1989 | 1605 | 0.020 |
Why?
|
| Heart Rate | 3 | 1988 | 4218 | 0.020 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2015 | 2048 | 0.020 |
Why?
|
| Neisseria meningitidis | 1 | 1987 | 111 | 0.020 |
Why?
|
| Serotyping | 1 | 1987 | 332 | 0.020 |
Why?
|
| Troponin | 1 | 2010 | 534 | 0.020 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 1991 | 1142 | 0.020 |
Why?
|
| Standard of Care | 1 | 2010 | 571 | 0.020 |
Why?
|
| ROC Curve | 1 | 2014 | 3624 | 0.020 |
Why?
|
| Calcium Channel Blockers | 1 | 1989 | 692 | 0.020 |
Why?
|
| Cardiac Output | 1 | 1988 | 838 | 0.020 |
Why?
|
| Acetylcholine | 1 | 1988 | 629 | 0.020 |
Why?
|
| Drug Combinations | 1 | 1991 | 2079 | 0.020 |
Why?
|
| Breast | 1 | 1974 | 1976 | 0.020 |
Why?
|
| Comparative Effectiveness Research | 1 | 2010 | 712 | 0.020 |
Why?
|
| Patient Care Planning | 1 | 2010 | 904 | 0.020 |
Why?
|
| Prosthesis Failure | 1 | 1990 | 1208 | 0.020 |
Why?
|
| Angina Pectoris | 2 | 1986 | 960 | 0.020 |
Why?
|
| Pharmaceutical Vehicles | 1 | 1984 | 57 | 0.010 |
Why?
|
| Clinical Protocols | 1 | 2010 | 1444 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2018 | 8730 | 0.010 |
Why?
|
| Myocardial Ischemia | 1 | 1995 | 2139 | 0.010 |
Why?
|
| Abscess | 1 | 1988 | 607 | 0.010 |
Why?
|
| Guidelines as Topic | 1 | 2010 | 1395 | 0.010 |
Why?
|
| Aspergillus fumigatus | 1 | 1985 | 158 | 0.010 |
Why?
|
| Patient Readmission | 1 | 2018 | 3308 | 0.010 |
Why?
|
| Time Factors | 7 | 1991 | 40271 | 0.010 |
Why?
|
| Necrosis | 1 | 1988 | 1621 | 0.010 |
Why?
|
| Alcoholic Intoxication | 1 | 1984 | 176 | 0.010 |
Why?
|
| Prospective Studies | 4 | 2014 | 54914 | 0.010 |
Why?
|
| Nitroprusside | 1 | 2003 | 272 | 0.010 |
Why?
|
| Verapamil | 1 | 2003 | 242 | 0.010 |
Why?
|
| Tomography, Emission-Computed | 1 | 1984 | 1123 | 0.010 |
Why?
|
| Aged, 80 and over | 2 | 2018 | 59680 | 0.010 |
Why?
|
| Massachusetts | 1 | 2014 | 8908 | 0.010 |
Why?
|
| Pancreatitis | 1 | 1988 | 1087 | 0.010 |
Why?
|
| Physiology | 1 | 2001 | 112 | 0.010 |
Why?
|
| Follow-Up Studies | 4 | 2014 | 39430 | 0.010 |
Why?
|
| Administration, Oral | 2 | 1985 | 4041 | 0.010 |
Why?
|
| Thallium Radioisotopes | 1 | 1999 | 139 | 0.010 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2001 | 447 | 0.010 |
Why?
|
| Platelet Function Tests | 1 | 2001 | 272 | 0.010 |
Why?
|
| Skin Diseases | 1 | 1988 | 1099 | 0.010 |
Why?
|
| Clinical Trials as Topic | 3 | 2010 | 8051 | 0.010 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2001 | 578 | 0.010 |
Why?
|
| Ascorbic Acid | 1 | 1981 | 658 | 0.010 |
Why?
|
| Risk Factors | 3 | 2018 | 74915 | 0.010 |
Why?
|
| Odds Ratio | 2 | 2003 | 9687 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 1988 | 3212 | 0.010 |
Why?
|
| Coronary Vessels | 1 | 1988 | 3122 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 1988 | 4572 | 0.010 |
Why?
|
| Arrhythmias, Cardiac | 1 | 1986 | 2258 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 20231 | 0.010 |
Why?
|
| Blood Pressure | 2 | 1988 | 8538 | 0.010 |
Why?
|
| Light | 1 | 2001 | 1357 | 0.010 |
Why?
|
| Infusions, Parenteral | 2 | 1985 | 398 | 0.010 |
Why?
|
| Acute Disease | 2 | 2000 | 7246 | 0.010 |
Why?
|
| Uric Acid | 1 | 1981 | 807 | 0.010 |
Why?
|
| Risk Assessment | 2 | 2010 | 24311 | 0.010 |
Why?
|
| Treatment Failure | 1 | 1999 | 2656 | 0.010 |
Why?
|
| Predictive Value of Tests | 2 | 2003 | 15460 | 0.010 |
Why?
|
| Point-of-Care Systems | 1 | 2001 | 1228 | 0.010 |
Why?
|
| Bilirubin | 1 | 1974 | 439 | 0.010 |
Why?
|
| United States | 1 | 2020 | 73121 | 0.010 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 1991 | 184 | 0.010 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1974 | 595 | 0.010 |
Why?
|
| Blood Platelets | 1 | 2001 | 2485 | 0.010 |
Why?
|
| Cholesterol, LDL | 2 | 1989 | 2396 | 0.010 |
Why?
|
| Peptides | 1 | 2001 | 4368 | 0.000 |
Why?
|
| Cyclosporins | 1 | 1988 | 216 | 0.000 |
Why?
|
| Heparin | 1 | 1994 | 1636 | 0.000 |
Why?
|
| Liver Function Tests | 1 | 1988 | 527 | 0.000 |
Why?
|
| Breast Neoplasms | 1 | 1974 | 21156 | 0.000 |
Why?
|
| Postoperative Complications | 1 | 1989 | 15880 | 0.000 |
Why?
|
| Double-Blind Method | 2 | 1994 | 12450 | 0.000 |
Why?
|
| Mastectomy | 1 | 1974 | 1852 | 0.000 |
Why?
|
| Heart Ventricles | 2 | 1989 | 3839 | 0.000 |
Why?
|
| Iron | 1 | 1974 | 1813 | 0.000 |
Why?
|
| Scleroderma, Systemic | 1 | 1989 | 349 | 0.000 |
Why?
|
| Case-Control Studies | 1 | 2003 | 22293 | 0.000 |
Why?
|
| Drug Therapy, Combination | 1 | 1994 | 6320 | 0.000 |
Why?
|
| Cohort Studies | 2 | 1999 | 41797 | 0.000 |
Why?
|
| Coronary Care Units | 1 | 1986 | 235 | 0.000 |
Why?
|
| Propranolol | 1 | 1986 | 493 | 0.000 |
Why?
|
| Antibodies, Monoclonal | 1 | 2001 | 9263 | 0.000 |
Why?
|
| Prednisone | 1 | 1988 | 1568 | 0.000 |
Why?
|
| Multicenter Studies as Topic | 1 | 1989 | 1727 | 0.000 |
Why?
|
| Streptococcal Infections | 1 | 1988 | 619 | 0.000 |
Why?
|
| Young Adult | 1 | 2010 | 60045 | 0.000 |
Why?
|
| Heart Failure | 1 | 1987 | 11857 | 0.000 |
Why?
|
| Aspirin | 1 | 1994 | 3139 | 0.000 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 1999 | 10358 | 0.000 |
Why?
|
| Cholesterol, HDL | 1 | 1988 | 1820 | 0.000 |
Why?
|
| Physical Exertion | 1 | 1984 | 669 | 0.000 |
Why?
|
| Multivariate Analysis | 1 | 1995 | 12096 | 0.000 |
Why?
|
| Radionuclide Imaging | 1 | 1986 | 1998 | 0.000 |
Why?
|
| Random Allocation | 1 | 1986 | 2399 | 0.000 |
Why?
|
| Arterial Occlusive Diseases | 1 | 1985 | 751 | 0.000 |
Why?
|
| Triglycerides | 1 | 1988 | 2465 | 0.000 |
Why?
|
| Animals | 3 | 1989 | 169418 | 0.000 |
Why?
|
| Metabolic Clearance Rate | 1 | 1981 | 363 | 0.000 |
Why?
|
| Dogs | 1 | 1985 | 3847 | 0.000 |
Why?
|
| Tissue Distribution | 1 | 1984 | 2298 | 0.000 |
Why?
|
| Angiography | 1 | 1986 | 1598 | 0.000 |
Why?
|
| Logistic Models | 1 | 1995 | 13324 | 0.000 |
Why?
|
| Cholesterol | 1 | 1989 | 2910 | 0.000 |
Why?
|
| Sensitivity and Specificity | 1 | 1995 | 14728 | 0.000 |
Why?
|
| Syndrome | 1 | 1985 | 3278 | 0.000 |
Why?
|
| Oxygen Consumption | 1 | 1985 | 1882 | 0.000 |
Why?
|
| Transplantation, Homologous | 1 | 1988 | 4834 | 0.000 |
Why?
|
| Retrospective Studies | 2 | 2003 | 81834 | 0.000 |
Why?
|
| Hybridization, Genetic | 1 | 1974 | 102 | 0.000 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1986 | 10784 | 0.000 |
Why?
|
| Species Specificity | 1 | 1974 | 2422 | 0.000 |
Why?
|
| Adolescent | 2 | 1988 | 89168 | 0.000 |
Why?
|
| Rabbits | 1 | 1974 | 4786 | 0.000 |
Why?
|
| Disease Models, Animal | 1 | 1985 | 18388 | 0.000 |
Why?
|
| Circadian Rhythm | 1 | 1974 | 2585 | 0.000 |
Why?
|
| Protein Binding | 1 | 1974 | 9376 | 0.000 |
Why?
|
| Sex Factors | 1 | 1974 | 10647 | 0.000 |
Why?
|